Our expertise for Healthcare & Life Sciences

FCF Healthcare & Life Sciences supports innovative growth companies in the MedTech, Pharma and TechBio sectors throughout the entire financing process. Our hybrid team of experienced investment bankers and an opinion-leading advisory board acts on an equal footing in both a medical-scientific and business context - with ambitious entrepreneurs as well as with leading international investors.

This substantive expertise, combined with structured and efficient project management, leads to convincing equity stories, excellent pitch decks and resilient financing models, which typically involve around 200 man-hours of work.

With the right equity story - well-founded, precisely told and supported by high-quality documentation - we can specifically address our target universe of healthcare & life sciences investors. More than 2,000 qualified investors and financiers known to us - including not only the leading and well-known, but also numerous less visible but highly relevant venture capital and private equity investors, family offices and strategic partners - enable us to address them efficiently and with high quality ("mass with class"). The ability to address a large number of the most relevant investors in the shortest possible time with an optimal equity story and convincing materials is one of the key added values of our team.

A successful, efficient approach process leads to a higher number of first investor calls, follow-up calls, site meetings and ultimately term sheets - and thus increases the competitive pressure in the interests of our clients. Only in this way can the core objectives of a financing round - valuation, volume, dilution and investor quality - be optimized. This is the second key added value of our approach: We turn our clients from terms takers into terms setters in every transaction.

Access to 1,500: family offices, venture capital, public institutions and secondary market
Development of a convincing equity story, pitch decks and tailor-made financial models
Precise investor matching with equity story
Complete management of the fundraising process and contract negotiations

Access to around 100 growth lenders
Leading advisor in Europe to the European Investment Bank (EIB)Expertise in syndicated loans
Creation of professional pitch decks and financial models
End-to-end support for credit processes and contract negotiations

Leyden Labs B.V.

European Investment Bank Debt Facility

€ 20 million

June 2025

Limmatech Biologics AG

Capital Increase

[amount confidential]

December 2023

Immunic AG

EIB Debt Facility

€ 25 million

October 2020

INDUSTRY EXPERTISE

Optimization of the equity story

Technology assessment

Pre-due diligence & science-based transaction selection

FINANCIAL EXPERTISE

Process management

Investor Relations

Data-driven market observation & efficient investor communication

INDUSTRY EXPERTISE

Optimization of the equity story

Technology assessment

Pre-due diligence & science-based transaction selection

FINANCIAL EXPERTISE

Process management

Investor Relations

Data-driven market observation & efficient investor communication

Biotechnology & Pharma

Medical technology & diagnostics

Digital health & artificial intelligence

New York

Munich/Garmisch

Dubai

Shanghai

We have a long-established US family office with global reach and access to leading US public and private life sciences investors with licensed broker-dealers, regulated by SEC / FINRA.

We are BaFin-regulated financing specialists for European life sciences companies with a focus on structuring and placing equity, debt and license transactions with investors worldwide.

Our BioScience Valuation Center is also based in Garmisch and supports you with evidence-based valuations in the areas of value, commercial, R&D and economics for pharmaceutical and biotechnology companies.

We offer access to a specialized management and advisory company with local and global market expertise and a strong network and door opener to large institutional investors and UHNIs in the Middle East, headquartered in Dubai, with offices in Vienna and Moscow.

We offer access to a Chinese investment and advisory company that provides life sciences companies with access to the Asian market. With a specialization in licensing and partnership transactions and access to local investors and the pharmaceutical industry, it offers the best options for our clients.

The FCF Healthcare & Life SciencesVenture Capital Monitor - USA is a monthly overview of financing trends in the venture capital sector with a focus on US healthcare & life sciences companies. As of the end of June 2025, we have identified the following current VC trends in the United States:

Total funding for Healthcare & Life Sciences amounts to EUR 19,813 million
Thus, the 2025 funding volume is 5% behind the previous year, which continues the negative trend in healthcare and life sciences funding in the US
Biotech/pharma received 44% of the total investment volume (EUR 8,766 million), with oncology as the strongest indication (26%)
In June, Dispatch Biotherapeutics secured the highest transaction volume with EUR 189 million, followed by Athelas with EUR 175 million and Commure with EUR 175 million
Subsequently, a mega financing of the equivalent of USD 1 billion for Retro, a BioTech with research in the field of the central nervous system, was announced in January
General Catalyst (United States) is the most active investor (by deal volume in 2025), followed by Illumina (United States) and ARCH Venture Partners (United States)

Download the latest report

The FCF Healthcare & Life Sciences Venture Capital Monitor Europeis a monthly overview of biotechnology, pharmaceutical, medical technology and healthcare technology companies that highlights trends in venture capital financing in the European life sciences industry. As of the end of June 2025, we have identified the following current VC trends in Europe:

Total funding for Healthcare & Life Sciences amounts to EUR 6,109 million
The financing volume is thus 33% above 2024, a strong increase compared to theprevious year
Biotech/pharma received 40% of the total investment volume (EUR 2,426 million), with metabolic disorders (incl. diabetes, obesity) as the strongest indication (23%)
In June, Juvenescence (Ireland) secured the highest transaction volume with EUR 132m, followed by SpliceBio (Spain) with EUR 119m and Draig Therapeutics (UK) with EUR 103m
GV (United States) is the most active investor (by deal volume in 2025), followed by Alphabet (United States) and Thrive Capital (United States)

Download the latest report

Financing solutions for the healthcare companies of tomorrow.

Financing instruments for your growth

Selected transactions

Leyden Labs B.V.

Limmatech Biologics AG

Immunic AG

Healthcare & Life Sciences Advisory Board

DR. ALEXANDRA GOLL, Managing Director at BioPharma Advisory

DR. MARION JUNG, Member of the FCF Advisory Board

ENNO SPILLNER, CFO at Formycon

AXEL POLACK, CEO at Polack Holding GmbH

Our references

Capital for visionaries - we combine innovation with investors

INDUSTRY EXPERTISE

FINANCIAL EXPERTISE

INDUSTRY EXPERTISE

FINANCIAL EXPERTISE

Financing expertise for industries of the future

Biotechnology & Pharma

Medical technology & diagnostics

Digital health & artificial intelligence

Your access to leading healthcare investors

Monthly insights on healthcare venture capital

Your contact persons

MATHIAS KLOZENBÜCHER

JOHANNES LINK